|
TNP-470
|
| Names
|
Preferred IUPAC name
[(3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl] N-(2-chloroacetyl)carbamate |
| Other names
TNP-470, O-(chloroacetylcarbamoyl)fumagillol
|
| Identifiers
|
|
|
|
|
|
|
| ChEBI
|
|
| ChEMBL
|
|
| ChemSpider
|
|
| DrugBank
|
|
| ECHA InfoCard
|
100.189.666 
|
| EC Number
|
|
|
|
|
| UNII
|
|
|
|
|
InChI=1S/C19H28ClNO6/c1-11(2)5-6-13-18(3,27-13)16-15(24-4)12(7-8-19(16)10-25-19)26-17(23)21-14(22)9-20/h5,12-13,15-16H,6-10H2,1-4H3,(H,21,22,23)/t12-,13-,15-,16-,18+,19+/m1/s1 Key: MSHZHSPISPJWHW-PVDLLORBSA-N
|
CC(=CC[C@@H]1[C@@](O1)(C)[C@H]2[C@@H]([C@@H](CC[C@]23CO3)OC(=O)NC(=O)CCl)OC)C
|
| Properties
|
|
|
C19H28ClNO6
|
| Molar mass
|
401.88 g·mol−1
|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). |
Chemical compound
TNP-470 is an methionine aminopeptidase 2 inhibitor. Although it was one of the first angiogenesis inhibitor tested in clinical trials, its potential was hampered by neurotoxic effects and lack of effectiveness.[1][2][3]
References
- ^ Goya Grocin, Andrea; Kallemeijn, Wouter W.; Tate, Edward W. (October 2021). "Targeting methionine aminopeptidase 2 in cancer, obesity, and autoimmunity". Trends in Pharmacological Sciences. 42 (10): 870–882. doi:10.1016/j.tips.2021.07.004. hdl:10044/1/102175. PMID 34446297. S2CID 237321716.
- ^ Kruger, E. A.; Figg, W. D. (June 2000). "TNP-470: an angiogenesis inhibitor in clinical development for cancer". Expert Opinion on Investigational Drugs. 9 (6): 1383–1396. doi:10.1517/13543784.9.6.1383. ISSN 1354-3784. PMID 11060750. S2CID 45149960.
- ^ Stadler, Walter M.; Kuzel, Timothy; Shapiro, Charles; Sosman, Jeffery; Clark, Joseph; Vogelzang, Nicholas J. (August 1999). "Multi-Institutional Study of the Angiogenesis Inhibitor TNP-470 in Metastatic Renal Carcinoma". Journal of Clinical Oncology. 17 (8): 2541–2545. doi:10.1200/JCO.1999.17.8.2541. ISSN 0732-183X. PMID 10561320.
|
